📊 PAVM Key Takeaways
Is PAVmed Inc. (PAVM) a Good Investment?
PAVmed is in severe financial distress with revenue collapsed 97.6% YoY to just $22K while operating losses reached $8M and operating cash burn is negative $2.6M. The company is destroying shareholder value (ROE -0.2%, ROA -0.1%) with no clear path to profitability, leaving only 2.5 years of cash runway at current burn rates if revenue does not recover.
PAVmed Inc. Key Strengths (PAVM)
- Moderate leverage ratio (0.38x Debt/Equity) provides some financial flexibility
- Current ratio of 2.02x indicates adequate short-term liquidity ($6.5M cash available)
- Substantial asset base of $45.4M relative to current market distress
PAVM Stock Risks: PAVmed Inc. Investment Risks
- Revenue collapse of 97.6% YoY indicates fundamental business failure or product rejection
- Operating cash burn of $2.6M annually will exhaust $6.5M cash reserves in approximately 2.5 years without revenue recovery
- Negative operating income of $8M and negative margins across all metrics indicate core business is fundamentally unprofitable
- Interest coverage of -309x cannot service $15M debt from operations; relies on asset liquidation or capital raises
- Company likely approaching going concern issues if revenue does not recover dramatically
Key Metrics to Watch
- Quarterly revenue trend - critical to determine if $22K represents bottom or continued deterioration
- Operating cash flow sustainability - cash burn trajectory will determine time to liquidity crisis
- Cash balance - current $6.5M is lifeline; depletion schedule is existential risk
- Product pipeline success or new revenue recognition - any material recovery in top-line essential for survival
PAVmed Inc. (PAVM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.02x current ratio provides a solid financial cushion.
PAVM Profit Margin, ROE & Profitability Analysis
PAVM vs Healthcare Sector: How PAVmed Inc. Compares
How PAVmed Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PAVmed Inc. Stock Overvalued? PAVM Valuation Analysis 2026
Based on fundamental analysis, PAVmed Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PAVmed Inc. Balance Sheet: PAVM Debt, Cash & Liquidity
PAVM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PAVmed Inc.'s revenue has grown significantly by 499% over the 5-year period, indicating strong business expansion. The most recent EPS of $14.90 reflects profitable operations.
PAVM Revenue Growth, EPS Growth & YoY Performance
PAVM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $8.0K | -$60.0K | $-4.42 |
| Q3 2025 | $5.0K | $1.7M | $-0.11 |
| Q2 2025 | $6.0K | $7.0M | $0.13 |
| Q1 2025 | $8.0K | -$15.2M | $0.34 |
| Q3 2024 | $791.0K | -$17.7M | $0.79 |
| Q2 2024 | $166.0K | -$10.8M | $-1.19 |
| Q1 2024 | $446.0K | -$15.2M | $-2.62 |
| Q3 2023 | $76.0K | -$17.7M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
PAVmed Inc. Dividends, Buybacks & Capital Allocation
PAVM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PAVmed Inc. (CIK: 0001624326)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PAVM
What is the AI rating for PAVM?
PAVmed Inc. (PAVM) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PAVM's key strengths?
Claude: Moderate leverage ratio (0.38x Debt/Equity) provides some financial flexibility. Current ratio of 2.02x indicates adequate short-term liquidity ($6.5M cash available).
What are the risks of investing in PAVM?
Claude: Revenue collapse of 97.6% YoY indicates fundamental business failure or product rejection. Operating cash burn of $2.6M annually will exhaust $6.5M cash reserves in approximately 2.5 years without revenue recovery.
What is PAVM's revenue and growth?
PAVmed Inc. reported revenue of $22.0K.
Does PAVM pay dividends?
PAVmed Inc. does not currently pay dividends.
Where can I find PAVM SEC filings?
Official SEC filings for PAVmed Inc. (CIK: 0001624326) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PAVM's EPS?
PAVmed Inc. has a diluted EPS of $-4.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PAVM's fundamental grade?
Based on our AI fundamental analysis in May 2026, PAVmed Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PAVM stock overvalued or undervalued?
Valuation metrics for PAVM: ROE of -0.2% (sector avg: 15%), net margin of -272.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PAVM's AI grade for 2026?
Our dual AI analysis gives PAVmed Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PAVM's free cash flow?
PAVmed Inc.'s operating cash flow is $-2.6M, with capital expenditures of $22.0K. FCF margin is -12,009.1%.
How does PAVM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -272.7% (avg: 12%), ROE -0.2% (avg: 15%), current ratio 2.02 (avg: 2).